Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| N/A | Nab-paclitaxel | Gastrointestinal cancer | Active | |||
| N/A | Nab-paclitaxel | Solid tumours | Reimburse with clinical criteria and/or conditions | Active | ||
| N/A | panitumumab | Left-sided metastatic colorectal cancer (mCRC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | everolimus | Renal angiomyolipoma associated with tuberous sclerosis complex | Reimburse with clinical criteria and/or conditions | Active | ||
| Naglazyme | Galsulfase (Drug Plan Submission) | Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) | List with clinical criteria and/or conditions | Complete | ||
| Nerlynx | Neratinib | ERBB2-positive breast cancer | Do not reimburse | Complete | ||
| Nesina | Alogliptin | Diabetes mellitus, type 2 | Do not list | Complete | ||
| Neulasta | Pegfilgrastim | Neutropenia | List with clinical criteria and/or conditions | Complete | ||
| Neupro | Rotigotine | Parkinson’s disease | List with clinical criteria and/or conditions | Complete | ||
| Neupro | Rotigotine | Parkinson's disease | Do not list | Complete |
Last Updated : July 28, 2024